ResearcherPennsylvania State UniversityNo recent work listed
Katelin Anne Mirkin
Matched on ORCID iD 0000-0002-0697-2316; OpenAlex author ID A5075978912. Sources: OpenAlex.
Their work
- Papers
- 9 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 4
2016: 2 papers · 2017: 4 papers · 2018: 3 papers
Papers 9
- Minimally invasive surgical approaches offer earlier time to adjuvant chemotherapy but not improved survival in resected pancreatic cancer. Co-author DOI 10.1007/s00464-017-5937-7↗
- Time to Surgery: a Misguided Quality Metric in Early Stage Pancreatic Cancer. Co-author DOI 10.1007/s11605-018-3730-0↗
- Correlation of clinical and pathological staging and response to neoadjuvant therapy in resected pancreatic cancer. Co-author DOI 10.1016/j.ijsu.2018.01.043↗
- Trends in utilization of neoadjuvant therapy and short-term outcomes in resected pancreatic cancer. Co-author DOI 10.1016/j.amjsurg.2016.08.015↗
- Greater lymph node retrieval and lymph node ratio impacts survival in resected pancreatic cancer. Co-author DOI 10.1016/j.jss.2017.06.076↗
- Utilization and trends in palliative therapy for stage IV pancreatic adenocarcinoma patients: a U.S. population-based study. First author DOI 10.21037/jgo.2017.06.01↗
- Prognostic impact of carbohydrate antigen 19-9 level at diagnosis in resected stage I-III pancreatic adenocarcinoma: a U.S. population study. Co-author DOI 10.21037/jgo.2017.07.04↗
- Time to the initiation of adjuvant chemotherapy does not impact survival in patients with resected pancreatic cancer. Co-author DOI 10.1002/cncr.30163↗
- Survival impact of neoadjuvant therapy in resected pancreatic cancer: A Prospective Cohort Study involving 18,332 patients from the National Cancer Data Base. Co-author DOI 10.1016/j.ijsu.2016.08.523↗
Closest collaborators
The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Christopher S. Hollenbeak · 9 shared papers, 2016–2018 · strength 0.99
- Paper Time to Surgery: a Misguided Quality Metric in Early Stage Pancreatic Cancer. DOI 10.1007/s11605-018-3730-0↗
- Paper Minimally invasive surgical approaches offer earlier time to adjuvant chemotherapy but not improved survival in resecte… DOI 10.1007/s00464-017-5937-7↗
- Paper Correlation of clinical and pathological staging and response to neoadjuvant therapy in resected pancreatic cancer. DOI 10.1016/j.ijsu.2018.01.043↗
- Joyce Y. Wong · 9 shared papers, 2016–2018 · strength 0.99
- Paper Time to Surgery: a Misguided Quality Metric in Early Stage Pancreatic Cancer. DOI 10.1007/s11605-018-3730-0↗
- Paper Minimally invasive surgical approaches offer earlier time to adjuvant chemotherapy but not improved survival in resecte… DOI 10.1007/s00464-017-5937-7↗
- Paper Correlation of clinical and pathological staging and response to neoadjuvant therapy in resected pancreatic cancer. DOI 10.1016/j.ijsu.2018.01.043↗
- Audrey Stokes Kulaylat · 1 shared paper, 2017 · strength 0.10
- Niraj Jaysukh Gusani · 1 shared paper, 2017 · strength 0.10
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.